Women of childbearing potential must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within  days prior to registration
Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin pregnancy test within  days prior to Day .
Negative pregnancy test (urine or serum beta human chorionic gonadotropin [b-hCG]) at Screening for women of child bearing potential who are sexually active
Negative urine ?-human chorionic gonadotropin (?-HCG) pregnancy test for fertile women at screening and confirmed by serum pregnancy test in the  hours prior to OPN- administration
Serum creatinine ?. mg/dL or a measured creatinine clearance ? mL/min; and Negative serum ? hCG (human chorionic gonadotropin) test in women of childbearing potential (defined as women ? years of age, or > years of age with a history of amenorrhea for ? months prior to study entry).
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within  days prior to the first dose of brentuximab vedotin and must agree to use an effective contraception method during the study and for  days following the last dose of study drug; females of non-childbearing potential are those who are post-menopausal for more than  year or who have had a bilateral tubal ligation or hysterectomy
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential
Women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial; pregnant women are excluded from this study; breastfeeding is not allowed during the course of the study; female patients must have a negative pregnancy test (human chorionic gonadotropin beta subunit [B-HCG] test in urine or serum) prior to commencing study treatment
Have a negative beta-human chorionic gonadotropin (?-hCG) pregnancy test at time of study entry and within  days prior to planned first dose of investigational product, and
Adolescent women/young women of childbearing potential must have a negative highly sensitive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at Screening before enrollment/randomization. Adolescent/young women who are pregnant or breastfeeding are ineligible for this study
Female of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test result within  days of first study dose; female patients who are surgically sterilized or who are >  years old and have not experienced menses for >  years may have beta-HCG pregnancy test waived
Patients who are women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented =<  days prior to registration
Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening
PART I: Negative serum beta human chorionic gonadotropin (HCG) if female and of childbearing potential
PART II: Negative serum beta HCG if of childbearing potential
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Pregnancy (absence to be confirmed by beta-human chorionic gonadotropin test in women of child-bearing potential) or lactation
Negative serum beta-human chorionic gonadotropin (HCG) in females, and agreement to the use of effective contraception in males and females of childbearing potential, IS REQUIRED
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within  days prior to registration
Positive urine pregnancy test (women of child bearing potential only) (QuickVue One Step human chorionic gonadotropin [hCG])
Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin or urine pregnancy test at screening
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening, within  hours of the first dose of anti-OX antibody, and every four weeks while on study treatment; women who are pregnant or breastfeeding are ineligible for this study
Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test either serum (Beta human chorionic gonadotropin [beta-hCG]) or urine
Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [hCG]) within  weeks of protocol entry if the patient is unsure of their pregnancy status. Patient signature declaring that they are not pregnant on the informed consent for treatment that is used in the Department of Radiation Oncology is also an acceptable substitution for a serum pregnancy test.
A woman of childbearing potential who is sexually active must have a negative pregnancy test (beta human chorionic gonadotropin [beta hCG]) at Screening (urine or serum)
Females of childbearing potential must have a negative beta human chorionic gonadotropin (?-hCG) pregnancy test result within  days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than  year or who have had a bilateral tubal ligation or hysterectomy.
Negative serum beta-human chorionic gonadotropin (hCG) pregnancy test within  hours of day  of induction chemotherapy in women of child-bearing potential
Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than  months after menopause
Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than  months after menopause; [women are considered postmenopausal if they are >=  months without menses, in the absence of endocrine or anti-endocrine therapies]
Female patients of childbearing potential must have a negative serum beta?human chorionic gonadotrophin (?-hCG) pregnancy test at screening and negative urine pregnancy test at Cycle  Day  prior to the first dose of study drug.
Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential
Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening and within  days prior to planned first dose of ribociclib
Female subjects of childbearing potential should have a negative urine or serum pregnancy test beta human chorionic gonadotropin (beta-hCG) within  hours prior to receiving the first dose of study medication
Negative beta-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential =<  days before starting neratinib therapy
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Negative urine or serum beta-human chorionic gonadotropin (BHCG) for women of childbearing potential only (within  days of registration)
For patients of childbearing potential, non-pregnant state, confirmed by negative serum or urine beta-human chorionic gonadotropin (HCG) within () days of planned radiation treatment
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Negative beta-human chorionic gonadotropin (hCG) pregnancy test within  weeks before enrollment for premenopausal women of reproductive capacity and for women less than  months after menopause; pregnancy screening will be conducted for women up to the age of  years per institutional standard
Negative urine beta-human chorionic gonadotropin (B-HCG) in women of child-bearing potential within  days prior to start of treatment
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening and must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within  hours prior to the first dose of treatment and must agree to use an effective contraception method to avoid pregnancy for  weeks ( days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drugs; females of non-childbearing potential are those who are postmenopausal greater than  year or who have had a bilateral tubal ligation or hysterectomy
Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within  hours of study start)
Negative serum or urine beta-human chorionic gonadotropin (beta-HCG) test (female of childbearing potential only), to be performed locally within the screening period
Negative serum or urine beta-human chorionic gonadotropin (B-HCG) test (female patient of childbearing potential* only), to be performed locally within the screening period
Women of child-bearing potential (WOCBP) must have a negative pregnancy test within  days of the first administration of study treatment; urine human chorionic gonadotropin (HCG) is an acceptable pregnancy assessment
Female patients of childbearing potential must have a negative serum pregnancy test (beta-human chorionic gonadotropin [hCG]) within  weeks of protocol entry
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of mobilization
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for female patients of childbearing potential
All post-menarchal females must have a negative serum beta-human chorionic gonadotropin (beta HCG); sexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least  months after
Patients may not be pregnant or breast feeding; females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within  days prior to the first dose of S-equol
Negative serum or urine pregnancy test beta-human chorionic gonadotropin (beta hCG) within  weeks prior to receiving the first dose of study medication for women of childbearing age
Negative pregnancy test (beta [B]-human chorionic gonadotropin [HCG]) within  days prior to registration for women of childbearing potential
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential within one week prior to enrollment
Negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening for patients of childbearing potential
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Women of childbearing potential must have a negative beta (B)-human chorionic gonadotropin (HCG) pregnancy test documented within  days prior to registration
Female patients with reproductive potential who do not have a negative urine or blood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening
Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) (to be performed within  days prior to start of study treatment)
Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [BhCG]) within  weeks of protocol entry
Females of childbearing potential (>  years old [yo]) must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test prior to initiation of cytoreductive therapy; sexually active patients will be informed of the risk of not using adequate contraception
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within  days prior to treatment
Negative serum or urine beta-human chorionic gonadotropin (b-hCG) pregnancy test at screening for patients of childbearing potential
DONOR: Not be pregnant as defined by negative serum (beta human chorionic gonadotropin [beta HCG]) pregnancy test in females of childbearing potential (non-childbearing potential defined as premenarchal, previous surgical sterilization, or postmenopausal for >  months)
Women of childbearing age must have a negative serum pregnancy test (beta-human chorionic gonadotropin) within  hours prior to initiating the conditioning regimen and be willing to not become pregnant by using effective contraception while undergoing treatment and for at least  months after the last dose of azacitidine
DLI DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within  week of beginning apheresis
Female patients of childbearing age will be excluded if they are pregnant as assessed by serum beta-human chorionic gonadotropin (b-HCG) or urine pregnancy test; a serum b-HCG test or urine pregnancy test will be performed no greater than  days prior to study registration
Female patient of childbearing potential must have a negative serum or urine pregnancy test beta-human chorionic gonadotropin (hCG) within  hours prior to receiving the first dose of study medication and agree to the use of effective methods of contraception while on study
Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [B HCG]) within  hours of receiving the first dose of rituximab
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within  days prior to taking the first dose of study medications
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (?-human chorionic gonadotropin) within  days prior to randomization.
For female patients of childbearing potential (i.e. have had a menstrual period within the past  months): a positive serum pregnancy test (?-human chorionic gonadotropin) within  days prior to enrollment.
and, have a negative serum pregnancy test at Screening, (Note: Subjects with elevated serum beta human chorionic gonadotropin (?hCG) and a demonstrated non-pregnant status through additional testing are eligible), and
A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at Screening and a negative urine pregnancy test prior to the first dose of study drug
Negative serum pregnancy test (serum HCG) within  days of study treatment if female and of childbearing potential (non-childbearing is defined as greater than one year post-menopausal surgically sterilized). Since beta-HCG may be falsely elevated as a result of malignancy, women of child-bearing potential who have an elevated serum beta-HCG level are eligible for enrollment if they have two Transvaginal Ultrasound (TVUS) scans one week apart along with serial beta-HCG levels two weeks apart that are inconsistent with pregnancy and a Gynecology consult to ensure that the beta- HCG level was at a value high enough to see pregnancy with TVUS.
Not pregnant based on a negative result on a serum human chorionic gonadotropin (HCG) test at screening Visit  and a negative urine pregnancy test prevaccination at Visit  (and at subsequent vaccination visits);
Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) performed locally within  hours (hrs) prior to first dose
Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential
Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (B-hCG) pregnancy test result within  days prior to the first dose of imipramine
Negative serum or urine beta-human chorionic gonadotropin (HcG) test (female patient of childbearing potential only) performed within  hours of prior to first study dose
Pregnancy test (urine or serum beta-human chorionic gonadotropin [HCG]) done within  hours before randomization must be negative (for women of childbearing potential only); if urine pregnancy results are positive or cannot be confirmed as negative, a serum pregnancy test will be required
A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin [b-hCG]) or urine test prior to the first dose of study drug
DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within two weeks of apheresis
Women of childbearing potential must have a negative serum ?-human chorionic gonadotropin or urine pregnancy test at screening
DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotrophin (HCG) test within three weeks of mobilization
Pregnancy during vaccine administration; female participants of childbearing potential must have a negative pregnancy test (serum beta human chorionic gonadotropin [B-HCG]) prior to administration of the first vaccine dose
Women who are pregnant or breastfeeding; women of child-bearing potential must have a negative pregnancy test (beta- human chorionic gonadotropin [B-HCG] test in urine or serum) prior to commencing study treatment
Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of childbearing potential only)
Women of childbearing potential must have a negative serum beta (B)-human chorionic gonadotropin (HCG) pregnancy test at initial screening and within  days prior to registration
Female patients of childbearing potential has a negative serum pregnancy test beta-human chorionic gonadotropin (hCG)
Woman of childbearing potential must have  negative highly sensitive serum (beta-human chorionic gonadotropin [b-hCG]) during screening, the first one within  to  days prior to the first dose of any component of study treatment and the second within  hours prior to the first dose of any component of study treatment
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Females of childbearing potential must have a negative beta human chorionic gonadotropin (?-hCG) pregnancy test result within  days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than  year or who have had a bilateral tubal ligation or hysterectomy.
Women of childbearing potential must have a negative urine or serum beta-human chorionic gonadotropin pregnancy test within  days prior to Day .
Female participants of childbearing potential must have  negative urine human chorionic gonadotropin tests within  to  days and within  hours prior to receiving study medication
Negative blood or urine beta-human chorionic gonadotropin (?- HCG) pregnancy test within  days prior to Day  for women of childbearing potential.
Female participants of reproductive potential must not be pregnant (negative urine or serum human chorionic gonadotropin test within  hours of study start)
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program
Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test result within  days prior to the first dose of ibrutinib; females of non-childbearing potential are those who are postmenopausal greater than  year or who have had a bilateral tubal ligation or hysterectomy
Negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening for patients of childbearing potential
Negative serum or urine beta-human chorionic gonadotropin (HCG) pregnancy test at screening for patients with childbearing potential
Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test result within  days prior to the first dose of SGN-; females of non-childbearing potential are those who are postmenopausal greater than  year or who have had a bilateral tubal ligation or hysterectomy
Negative serum pregnancy test (beta human chorionic gonadotropin [beta HCG]) within  days of starting study, if of child-bearing potential
A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta- hCG]) at Screening within  days prior to study drug administration Inclusion Criteria for Crossover:
Pregnancy or breast feeding; female patients must have a negative pregnancy test (beta-human chorionic gonadotropin [HCG] test in urine or serum) prior to commencing study treatment and must agree with the use of effective contraception during the study and for three months following last dose of nintedanib
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
Female participants must not be pregnant (negative urine or serum human chorionic gonadotropin test within  hours of study start)
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [Beta-hCG]) pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
Negative pregnancy test (serum beta-human chorionic gonadotropin [B-HCG]) within  days of starting study treatment is required in women of childbearing potential; NET patients with positive B-HCG are eligible if pregnancy can be excluded by vaginal ultrasound or lack of expected doubling of B-HCG
Negative serum pregnancy test (beta-human chorionic gonadotropin [B-hCG]) within  hours before starting study treatment for all women of childbearing potential
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within  days prior to treatment
DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within  week of beginning growth factor of choice
Negative urine beta-human chorionic gonadotropin (HCG) or negative serum quantitative beta-HCG or within  weeks prior to registration for women of childbearing potential
Negative serum human chorionic gonadotrophin (HCG) pregnancy test for premenopausal women of reproductive capacity and for women less than  months after menopause
Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than  months after menopause
Women of childbearing potential (including premenopausal women and women less than  months after menopause) must have a negative beta-human chorionic gonadotropin (hCG) urine pregnancy test within  weeks of registration
Premenopausal women of child bearing potential must have a normal urine or serum beta-human chorionic gonadotropin (HCG) prior to enrollment, and must agree to use effective contraception during treatment with nivolumab and for at least  months following the last dose of nivolumab
Women of childbearing potential must have a negative pregnancy test (serum or urine beta human chorionic gonadotropin [HCG]) prior to initiation of chemotherapy; both female and male breast cancer patients who are sexually active have to agree to practice contraception while participating in the trial and for  month after completion of therapy
Patients will be excluded if they are pregnant as assessed by serum beta human chorionic gonadotropin (b-HCG); a serum b-HCG test will be performed no greater than  days prior to study registration for women of childbearing potential
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Females of child-bearing potential (pre-menopausal) must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test at screening
Negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test within  hours of day  of induction chemotherapy in women of child-bearing potential
Negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test within  hours of day  of treatment with ABVD in women of child-bearing potential
Urine or serum beta-human chorionic gonadotropin (HCG) or serum HCG = negative (if female patient of childbearing potential)
Female patients with reproductive potential who do not have a negative urine or blood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening
Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within  hours of start of therapy
Female patient of childbearing potential must have a negative serum or urine pregnancy test (beta-human chorionic gonadotropin [hCG]) within  hours prior to receiving the first dose of study medication and agree to the use of effective methods of contraception while on study
Female patient of childbearing potential has a negative serum pregnancy test beta-human chorionic gonadotropin (b-hCG) within  days prior to receiving the first dose of vorinostat
Female patients of childbearing potential (WOCBP) must have a negative serum pregnancy test beta-human chorionic gonadotropin (hCG) within  days of the first treatment
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery)
Negative serum beta human chorionic gonadotropin (?hCG) test (for women of childbearing potential only)
Patients of childbearing potential must agree to use some form of adequate birth control during the periods they receive chemotherapy and any post-chemotherapy medications related to the transplant; females of child bearing potential must have a negative serum beta-human chorionic gonadotropin (B-HCG) within  week of starting therapy
DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within  week of beginning G-CSF mobilization
Female participants must not be pregnant (negative urine or serum human chorionic gonadotropin test at screening and again within  hours prior to receiving the first dose of study therapy)
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) or urine pregnancy test at screening
Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) pregnancy test at screening; pregnancy testing is not required for: (a) women who have been post-menopausal for at least  years without menses; or (b) women who are surgically sterile (e.g. by means of hysterectomy, tubal ligation, etc.)
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening within  days of enrollment
Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within  hours of study start)
Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only), to be performed locally within the screening period
Negative beta human chorionic gonadotropin (bHCG) within  days prior to study entry if patient is pre or perimenopausal
Negative pregnancy test (beta human chorionic gonadotropin [HCG]) within  days of study drug initiation for pre- or perimenopausal subjects with an intact uterus
Negative serum beta-human chorionic gonadotropin (B-HCG) test (female patient of childbearing potential only) performed locally within  hrs prior to first dose
If a female patient is of childbearing potential, she must have a negative serum pregnancy test (beta-human chorionic gonadotropin [hCG]) documented within  hours of the first administration of study drug
Male or non-pregnant and non-lactating female; if a female patient is of childbearing potential, she must have a negative serum pregnancy test (beta-human chorionic gonadotropin [b-hCG]) documented within  hours of the first administration of study drug
Negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening for patients of childbearing potential
A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening
Have a negative pregnancy test Beta Human Chorionic Gonaditrophin(-hCG) as verified by the study doctor within  hours prior to starting study therapy.
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test within  days of day (D) of neoadjuvant chemotherapy for women of childbearing potential
If female patient is of child bearing potential, she must have a negative serum pregnancy test (beta human chorionic gonadotropin [hCG]) documented up to  hours (hrs) prior to administration of first study drug
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within  days prior to the first dose of brentuximab vedotin and must agree to use an effective contraception method during the study and for  days following the last dose of study drug; females of non-childbearing potential are those who are postmenopausal greater than  year or who have had a bilateral tubal ligation or hysterectomy
Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) performed locally within  hours (hrs) prior to first dose
Negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening, performed no more than  hours prior to treatment initiation; for women of childbearing potential
A positive urine and/or serum beta-human Chorionic Gonadotropin pregnancy test
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within  days prior to registration
Patients of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin) within  hours prior to receiving the first dose of study treatment.
Female patients of childbearing potential must have a negative serum pregnancy test (human chorionic gonadotropin beta subunit [B-hCG] pregnancy test) within  hours prior to receiving the first dose of vorinostat; male patients enrolled in this study should also agree to use an adequate method of contraception for the duration of the study
DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within  week of beginning apheresis
Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only)
Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [b-hCG]) or urine pregnancy test within  days prior to treatment initiation and when clinically indicated every  weeks +/-  days while receiving study drugs, as shown in study calendar; women who are pregnant or breastfeeding are ineligible for this study
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Within  weeks of therapy start, women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening and must adhere to the scheduled pregnancy testing
Negative serum beta (?) human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within  hours prior to first dose
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within  days prior to registration
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study
A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum beta-human chorionic gonadotrophin [beta-hCG] test) in females of reproductive potential), not lactating or if of reproductive potential agrees to follow one of the options listed in protocol from  days prior to the first dose of study medication and until  days after the last dose of study treatment.
Negative beta-human chorionic gonadotropin (betaHCG) pregnancy test among females of childbearing age
Pregnancy or breast feeding; female patients with child-bearing potential must have a negative pregnancy test (beta-human chorionic gonadotropin [B-HCG] test in urine or serum) prior to commencing study treatment
If a female of child-bearing potential, must not be pregnant or planning to become pregnant during the study\r\n* Women <  years old must have a negative pregnancy test (urine human chorionic gonadotropin [HCG] or serum betaHCG) within  weeks of beginning chemotherapy
Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of apheresis
Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
Women of childbearing age will be required to have a negative human chorionic gonadotropic (HCG) test within seven days of surgery
Minocycline trial only: patients who are pregnant; pregnancy will be confirmed by negative urine test; patients with a positive urine test will be retested for doubling of human chorionic gonadotropin (HCG)  hours after the first test; patients without such a rise will be eligible for the study and will be enrolled at the investigators discretion
Female subjects capable of reproduction must have a negative beta human chorionic gonadotropin (BHCG) serum or urine pregnancy test result within  days prior to first Investigational Product dose
Negative pregnancy test (females of child bearing potential) within =<  week of rasburicase dose and use of efficient contraceptive method (both males and females); pregnancy test may be performed on serum (human chorionic gonadotropin [HCG]) or urine (HCG)
RECIPIENT: Negative serum or urine beta?human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
Women of child-bearing potential must also have a negative urine pregnancy test (beta-human chorionic gonadotropin [HCG]) within  hours of receiving treatment
Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of childbearing potential only)
Women of childbearing potential, unless they have had a negative urine beta human chorionic gonadotropin (betaHCG) within the previous  hours of the procedure
All post-menarchal females must have a negative beta-human chorionic gonadotropin (HCG) within  weeks prior to receiving the dose of I-MIBG; males and females of childbearing potential must practice an effective method of birth control while participating on this study, to avoid possible damage to the fetus
Women of childbearing potential, unless they have had a negative urine human chorionic gonadotropin (HCG) within the previous  hours of the procedure
Negative serum ? -HCG (beta human chorionic gonadotropin) test for female of child bearing potential at screening and a negative urine pregnancy test at Day .
Subjects who are pregnant or nursing; urine pregnancy test/or serum human chorionic gonadotropin (HCG) will be performed on women of child bearing potential
Women of childbearing potential must have a negative beta-human chorionic gonadotropin pregnancy test documented within  days prior to treatment. Have given written informed consent prior to any study-specific procedures.
Negative urine or serum beta-human chorionic gonadotropin (?-HCG) pregnancy test within  days prior to the Cycle , Day  visit, for women of childbearing potential.
